Date: 2018-09-13
Type of information: Construction of new premises
Compound:
Company: Oxford Biomedica (UK)
Therapeutic area:
Type agreement: construction of new premises
Action mechanism:
Disease:
Details:
- • On September 13, 2018, Oxford BioMedica announced that it has signed a fifteen year lease on a new facility in Oxford that is close to its Windrush Court headquarters.
- The new facility is approx. 84,000 sqft (7,800 sqm). The group’s planned Phase I and Phase 2 expansion will fit out around 45,000 sqft (4,200 sqm) for four GMP clean room suites and two fill and finish suites as well as offices, warehousing and QC laboratories, with space available for future expansion. Once open, the facility will more than double the group’s bioprocessing capacity. The plan is to open the new offices and warehouse in Q1 2019, with the additional GMP suites being ready in Q1 2020.
- This new full-service site, fully funded through the successful placing in March 2018, will allow the group to exploit the immediate market opportunity, meet the expected long-term demand and futureproof Oxford BioMedica’s market leading position. This new facility secures Oxford as a bioprocessing centre for Oxford BioMedica and will create up to 100 new, highly skilled positions at the group over the next two years.
Financial terms:
Latest news:
Is general: Yes
